|Day's range||46.385 - 46.385|
|52-week range||45.800 - 58.090|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
The chief executive of Shire has questioned investors' valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price. Flemming Ornskov also ...
A breakthrough cancer therapy that can wipe out leukemia in some deathly ill children and young adults comes with an expensive, long-lasting side effect.
Following a 14-percent pullback in shares of Shire PLC (ADR) (NASDAQ: SHPG ) since May 26, Bernstein said it expects a rebound, although expressed skepticism regarding a sustained rally. Analyst Aaron ...